Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Pfizer Inc Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Pfizer Inc announced that the PROFILE 1007 study met its primary endpoint, demonstrating that XALKORI (crizotinib) significantly improved progression-free survival (PFS) when compared with pemetrexed or docetaxel, in previously treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). PROFILE 1007 is the first randomized Phase 3 study in ALK-positive advanced NSCLC patients. The adverse events observed on crizotinib and chemotherapy in PROFILE 1007 were generally consistent with their respective known adverse event profiles.
Latest Developments for Pfizer Inc
- Pfizer Inc Halts Study Of Lymphoma Drug Unlikely To Help Survival-Reuters
- Pfizer Inc Lowers FY 2013 Guidance
- European Regulators Reject Pfizer Inc's Arthritis Drug-Reuters
- Pfizer IncPfizer’s Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
- Share this
- Link this
- Digg this
Follow Reuters